| Autor: |
Ovejero‐Benito, M.C., Muñoz‐Aceituno, E., Sabador, D., Reolid, A., Llamas‐Velasco, M., Prieto‐Pérez, R., Abad‐Santos, F., Daudén, E. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Jun2020, Vol. 34 Issue 6, pe271-e275, 5p |
| Abstrakt: |
Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis We recruited 120 patients with moderate-to-severe plaque psoriasis from the Dermatology Department of "Hospital Universitario La Princesa" in Madrid treated with etanercept (52.5%), adalimumab (30.8%) and/or ustekinumab (16.7%) (Fig. a). 50/120 patients were subjected to a second biological drug cycle and 13 to a third cycle (total 183 cycles). New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text